TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Free Report) - Stock analysts at Roth Capital dropped their Q2 2025 earnings estimates for shares of TriSalus Life Sciences in a research note issued on Wednesday, May 21st. Roth Capital analyst J. Wittes now expects that the company will post earnings of ($0.19) per share for the quarter, down from their prior forecast of ($0.11). The consensus estimate for TriSalus Life Sciences' current full-year earnings is ($1.55) per share. Roth Capital also issued estimates for TriSalus Life Sciences' Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.72) EPS and FY2026 earnings at ($0.29) EPS.
TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.13). The company had revenue of $9.17 million during the quarter, compared to the consensus estimate of $9.04 million. During the same quarter last year, the firm posted ($0.60) EPS.
Other equities analysts have also recently issued research reports about the stock. Canaccord Genuity Group reaffirmed a "buy" rating and set a $11.00 price objective on shares of TriSalus Life Sciences in a research note on Friday, March 28th. Lake Street Capital began coverage on shares of TriSalus Life Sciences in a research note on Thursday, February 13th. They issued a "buy" rating and a $10.00 target price on the stock. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $10.93.
Get Our Latest Stock Report on TLSI
TriSalus Life Sciences Price Performance
Shares of TLSI traded down $0.05 during midday trading on Friday, hitting $5.54. 16,554 shares of the company traded hands, compared to its average volume of 42,413. TriSalus Life Sciences has a one year low of $3.50 and a one year high of $7.90. The firm has a market cap of $178.79 million, a P/E ratio of -2.22 and a beta of 0.50. The stock has a 50-day moving average of $5.43 and a 200-day moving average of $5.07.
Institutional Investors Weigh In On TriSalus Life Sciences
A number of large investors have recently added to or reduced their stakes in TLSI. Geode Capital Management LLC increased its position in shares of TriSalus Life Sciences by 1.9% during the 4th quarter. Geode Capital Management LLC now owns 204,137 shares of the company's stock valued at $1,023,000 after purchasing an additional 3,710 shares during the last quarter. Bank of America Corp DE grew its position in TriSalus Life Sciences by 120,471.6% during the fourth quarter. Bank of America Corp DE now owns 178,446 shares of the company's stock valued at $894,000 after acquiring an additional 178,298 shares during the last quarter. Bridgeway Capital Management LLC grew its position in TriSalus Life Sciences by 333.3% during the fourth quarter. Bridgeway Capital Management LLC now owns 65,000 shares of the company's stock valued at $326,000 after acquiring an additional 50,000 shares during the last quarter. Goldman Sachs Group Inc. purchased a new position in shares of TriSalus Life Sciences during the first quarter worth approximately $187,000. Finally, Northern Trust Corp lifted its holdings in shares of TriSalus Life Sciences by 22.7% in the 4th quarter. Northern Trust Corp now owns 32,112 shares of the company's stock worth $161,000 after acquiring an additional 5,936 shares during the last quarter. Hedge funds and other institutional investors own 2.58% of the company's stock.
Insider Activity at TriSalus Life Sciences
In related news, insider Richard Marshak sold 6,597 shares of the company's stock in a transaction on Monday, May 19th. The shares were sold at an average price of $5.18, for a total value of $34,172.46. Following the completion of the transaction, the insider now directly owns 69,101 shares in the company, valued at approximately $357,943.18. The trade was a 8.71% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 16,125 shares of company stock valued at $83,528 over the last three months. 27.50% of the stock is owned by corporate insiders.
About TriSalus Life Sciences
(
Get Free Report)
TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.
See Also
Before you consider TriSalus Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TriSalus Life Sciences wasn't on the list.
While TriSalus Life Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
